Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
|Articles|December 1, 2012
Midurethral sling use for stress urinary incontinence rose over 9-year period
A study investigating trends in ambulatory surgery for stress urinary incontinence shows a significant fourfold increase in the annual rate of sling procedures performed over a contemporary 9-year period, and yet, submucosal injection therapy appears to be maintaining a niche for the treatment of certain patients, report researchers from the University of Michigan, Ann Arbor.
Advertisement
Advertisement
Related to this article
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
3
Experts review evidence on testosterone and prostate cancer
4
Carotuximab plus apalutamide shows interim PFS benefit in mCRPC
5